Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9H9Y6

UPID:
RPA2_HUMAN

ALTERNATIVE NAMES:
DNA-directed RNA polymerase I 135 kDa polypeptide

ALTERNATIVE UPACC:
Q9H9Y6; B7Z6Y7; B7Z823; F5GZX4; F8W898; Q2TAM4; Q585T5; Q6ZRR2; Q9H9D3

BACKGROUND:
The DNA-directed RNA polymerase I subunit RPA2 is integral to the transcription machinery, acting as the second largest core component of RNA polymerase I. This enzyme is vital for the production of ribosomal RNA precursors, indicating its essential role in cellular function and growth.

THERAPEUTIC SIGNIFICANCE:
RPA2's association with Treacher Collins syndrome 4 highlights its importance in craniofacial development. Exploring the functions of DNA-directed RNA polymerase I subunit RPA2 offers promising avenues for developing treatments for related craniofacial abnormalities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.